No Alzheimer's benefits in supplements - NIH panel
This article was originally published in The Tan Sheet
Data do not support the association of dietary supplement intake and drug regimens with reduced risk of Alzheimer's disease, says a National Institutes of Health panel. Following a state-of-the-science conference April 26-28 in Bethesda, Md., the panel said in a 1statement that longer chain omega-3 fatty acids demonstrate some reduced risk of cognitive decline in longitudinal studies and "may provide new insight into the prevention or delay of cognitive decline or Alzheimer's." Other nutritional interventions, including folate, beta-carotene and vitamins B, E and C, show no consistent cognitive benefits, the panel said. Products touting support for brain and memory health products are a growing supplement segment (2"The Tan Sheet" Dec. 21, 2009)
You may also be interested in...
Ovos Natural Health plans a 2010 U.S. launch of its Vivimind cognitive health supplement, contingent upon FDA's go-ahead
The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines.
The final shortlist of contenders has been unveiled for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt on 2 November.